PHARMACY

BMS to acquire biologics developer for $430 million

BY Drew Buono

PRINCETON, N.J. Bristol-Myers Squibb has signed an agreement with Adnexus Therapeutics, under which BMS will acquire Adnexus, a developer of a new therapeutic class of biologics called Adnectins.

Under the agreement, Adnexus will become a subsidiary of BMS and advance BMS’ biologics, with its Phase I oncology biologic, Angiocept.  BMS will acquire all of Adnexus’ issued and outstanding shares of stock for $430 million.  There also is another $75 million that could be paid to Adnexus, in three separate payments, depending on development and regulatory milestones.

“Bringing Adnexus into the Bristol-Myers Squibb family builds upon a successful and productive collaboration between the two companies in oncology and is an important step in accelerating the strategic transformation of our pharmaceutical business to a biopharma business model,” said Jim Cornelius, chief executive officer of BMS.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Democrats vow to re-examine Medicare provisions, Baucus says

BY Allison Cerra

WASHINGTON Cuts in Medicare payments to private health insurers won’t be included in a children’s health bill, leaving the program at a standstill, a Wall Street Journal article reports.

Unless Congress and the White House agree to the funding of the State Children’s Health Insurance Program, which expires at the end of September, approximately five million children will be left uninsured. To mitigate this, Montana Sen. Max Baucus, the chairman of the Senate committee that oversees Medicare, has debated with the idea of cutting payments to Medicare Advantage insurers and increasing taxation on tobacco products to balance the lack of funding.

Baucus also said that the Medicare committee wishes to improve other aspects of the program, including improvements in having health insurers pay retail pharmacies immediately following the dispensing of medications.

Senate Democrats, led by Baucus, have passed a bill by a margin of 68 to 31 to increase funding by $35 billion. The House Democrats’ bill, sponsored by Michigan’s John Dingell, passed 225 to 204 and increases that amount to $50 billion.

President Bush, on the other hand, wishes to increase the budget of the children’s health bill by a comparatively small $5 billion over five years, and treat the federal-state health insurance policy the same way the government treats food and housing—which is, making it available to low-income families only.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

U.S. goverment to sponsor 10 ImClone cancer trials

BY Drew Buono

WASHINGTON The U.S. government will sponsor 10 clinical trials of ImClone Systems’ compound IMC-A12 to treat cancer in the breast, bones, liver, lung, pancreas, and other organs. The compound blocks a receptor on tumor cells that are needed for their development, by acting against a protein called insulin-like growth- factor type 1 receptor, which stops the cells from growing and dividing.

According to Eric Rowinsky, ImClone’s chief medical officer, “Because the insulin-like receptor appears to be active in so many cancers, the co zmpany plans to test IMC-A12 in at least eight types of cancer. The fact that the cancer institute will also conduct 10 trials doubles our capacity right off the bat.”

The company is years away from seeking approval for the drug, but did just begin the second stage of human tests for colon cancer with it.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?